Tesaro's Varubi: Safety, Dosing Convenience Could Drive Third NK-1 Inhibitor
FDA approval for prevention of chemotherapy induced nausea and vomiting in delayed phase after chemo paves way for fourth-quarter market entry.
FDA approval for prevention of chemotherapy induced nausea and vomiting in delayed phase after chemo paves way for fourth-quarter market entry.